Additive system for protein PEGylation
By using p-aminobenzoyl hydrazine or a combination thereof as additives, the protein polyethylene glycolation reaction was optimized, solving the problems of slow reaction rate and low conversion rate, and achieving efficient and stable protein polyethylene glycolation.
Patent Information
- Application Number
- CN202211743414.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2015-11-23
- Filing Date
- 2016-11-22
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2036-11-22
AI Technical Summary
Existing technologies for the polyethylene glycolation of proteins suffer from slow reaction rates, low conversion rates, and the need for high temperatures and high concentrations of toxic catalysts, resulting in compromised yields and product stability.
p-Aminobenzoyl hydrazide or its combination with aromatic amines or ammonium salts was used as an additive for the conjugation reaction of proteins with PEG reagents. The conversion rate and rate were improved by optimizing the reaction conditions.
High-conversion polyethylene glycolation was achieved at a low PEG:protein molar ratio, avoiding the use of high temperatures and toxic substances, and improving reaction efficiency and product stability.
Smart Images

Figure CN115819494B_ABST
Abstract
Description
[0001] This application is a divisional application of the invention patent application filed on November 22, 2016, with application number 201680067897.7 and entitled "Additive System for Polyethylene Glycolization of Proteins".
[0002] Cross-references to related applications This patent application claims the benefit of provisional patent application 62 / 258644, filed November 23, 2015, the teachings of which are expressly incorporated herein by reference. Technical Field
[0003] This disclosure relates to improved additive systems for protein PEGylation reactions. Specifically, this disclosure identifies additives for conjugation reactions between proteins containing p-acetylphenylalanine residues and aminooxy-PEG compounds.
[0004] Background: Protein PEGylation is a conjugation process involving the linking of a polyethylene glycol derivative to a therapeutic protein to improve its stability and pharmacokinetics by reducing clearance and providing steric sanctuary protection against proteolytic enzymes and the immune system (Robens, MJ et al., Adv. Drug Delivery Rev., 54:459 (2002)). Generally, PEGylation techniques can be categorized into two types: random and site-specific conjugation. Random PEGylation arbitrarily links a PEGylating agent to reactive amino acids such as lysine or cysteine to provide a mixture of PEGylated products. Conversely, site-specific conjugation utilizes the explicit reactivity of native functional groups (e.g., N- or C-terminal groups) or non-native amino acids (e.g., p-acetylphenylalanine-pAcF) to control the position and number of PEG residues linked to the protein. Site-specific conjugation reactions involving ketoxime formation between polyethylene glycolating agents and pAcF residues are incorporated into substrate proteins via genetic code amplification (Liu, CC et al., Annu. Rev. Biochem., 79:413 (2010); Tian, F et al., "Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides", U.S. Patent No. 7,468,458 (December 23, 2008)). Despite their proven utility, ketoxime-based conjugations are impaired by slow rates and incomplete conversion (Crisalli, P. et al., J. Org. Chem., 78:1184 (2013)). Attempts to improve ketoxime formation have included the use of excess polyethylene glycolating agents, high temperatures, or high concentrations of toxic catalysts. However, these solutions introduce additional steps to remove excess polyethylene glycolating agents or toxic catalysts from the product and often compromise protein stability. Furthermore, the old method did not use additives, but instead used a denaturing agent (urea) and / or acetylhydrazine (AcNHNH2) as an additive. AcNHNH2 and related structures have been defined in PCT Publication No. WO 2007 / 056448.
[0005] There is a need in the art for novel methods to improve the yield and rate of PEGylation of proteins containing pAcF residues (relaxin and FGF21) by examining the mechanical mechanisms influencing stall and by identifying new additives that accelerate the reaction and promote high conversion rates at low PEG:protein molar ratios. This method should be economical, promote higher conversion rates with very low amounts of PEGylating agents, and facilitate faster reactions, avoiding the need for high reaction temperatures and the removal of genotoxic substances.
[0006] Overview In a first embodiment, this disclosure provides an improved additive system for protein polyethylene glycolation reactions, the system comprising p-aminobenzoyl hydrazide alone or in combination with an aromatic amine or an ammonium salt.
[0007] In another embodiment, this disclosure provides a method for obtaining polyethylene glycol-modified proteins, the method comprising the steps of: identifying a protein, a PEG reagent, and an additive system; and dissolving the protein and then mixing the protein with the PEG reagent in the presence of the additive system to obtain the polyethylene glycol-modified protein in high yield.
[0008] In another embodiment, this disclosure provides a pharmaceutical composition comprising a polyethylene glycol-modified protein obtained by the methods mentioned in the above embodiments, for the treatment of an individual in need of it. Brief description of the attached diagram Figure 1 The general mechanism of ketoxime formation.
[0009] Figure 2 Chromatogram of relaxin (4 mg / mL, in water) PEGylated with 20 kDa PEG-OA reagent.
[0010] Figure 3 Time course of 20 kDa PEG-OA decomposition in water when exposed to a continuous airflow.
[0011] Figure 4 Using in-situ IR and 1 The stability of acetylhydrazine was studied using 1H NMR spectroscopy.
[0012] Figure 5 Model reaction for screening additives. Reaction conditions: 1 (36 mmol) and 2 (36 mmol), in 1.0 mL acetate buffer (20 mM, pH 4.0), at room temperature (23 °C).
[0013] Figure 6 The relative rates (k) observed for different additives rel Acetylhydrazine (k) rel ≈2) Displayed in the box.
[0014] Figure 7 Time progression of the reaction of dipeptide 1 with O-benzylhydroxylamine (2) in the presence of (a) 1 equivalent of pyrazolamide (red); (b) 1 equivalent of MCH (blue); (c) 1 equivalent of pyrazolamide and 1 equivalent of MCH (green). The reaction curves obtained without additives are shown in gray.
[0015] Figure 8Samples containing dipeptide 1 (a) (blue) and (b) 1 equivalent of MCH (green); (c) 1 equivalent of MCH and 1 equivalent of pyrazolamide (gray); (d) 1 equivalent of pyrazolamide (red). 1 Aromatic region of 1H NMR spectrum. The synergistic effect between MCH and pyrazolamine additives produces a mixture with higher concentrations of active intermediates compared to samples containing only one additive.
[0016] Figure 9 Left: Polyglycolation of dipeptide 1 with 30 equivalents of PABH and 12 equivalents of 20 kDa PEG-OA; the hydrazone intermediate is traced as a green dot. Right: Polyglycolation reaction in which 1.2 equivalents of the PEGylation reagent are added after the dipeptide has been equilibrated with 30 equivalents of PABH overnight.
[0017] Figure 10 Left: Graph of hydrazone concentration versus PABH equivalent for dipeptide-1 PEGylation; blue dots indicate reaction mixtures where pyrazolamine is omitted. Middle: Effect of different combinations of PABH and pyrazolamine on reaction rate. Right: Final concentrations of dipeptide-1 and its hydrazone derivatives in reaction mixtures containing PABH and pyrazolamine.
[0018] Figure 11 : A graph showing the remaining dipeptide 1 at the end of the reaction as a percentage of total additive equivalents and the pyrazolamide:PABH ratio.
[0019] Figure 12 Left: Time course of the reaction of relaxin with 20 kDa PEG-OA (15 equivalents) in the presence of (a) 30 equivalents of acetylhydrazine (blue); (b) 30 equivalents of MCH (red); the reaction curve obtained without additives is shown in gray. Middle: Time course of the reaction of relaxin with PEG-OA (15 equivalents) in the presence of (a) 30 equivalents of pyrazolamide (blue); (b) 30 equivalents of MCH (red); (c) 10 equivalents of MCH (purple); (d) 30 equivalents of pyrazolamide and 10 equivalents of MCH (green); (e) 30 equivalents of MCH and 30 equivalents of pyrazolamide. Right: Time course of the reaction of relaxin with PEG-OA (15 equivalents) in the presence of 30 equivalents of pyrazolamide and 10 equivalents of MCH at (a) 40 °C; (b) 10 °C; (c) 25 °C.
[0020] Figure 13Left: Time course of the reaction of relaxin with 20 kDa PEG-OA (1.2 equivalents) in the presence of (a) 30 equivalents of MPCH and 30 equivalents of pyrazolamide (green); (b) 30 equivalents of pH and 30 equivalents of pyrazolamide (blue); and (c) 30 equivalents of MCH and 30 equivalents of pyrazolamide / urea 6M (red). Right: Time course of the reaction of relaxin with PEG-OA (1.2 equivalents) in the presence of (a) 30 equivalents of pH and 60 equivalents of pyrazolamide (blue); (b) 30 equivalents of acetylhydrazine and 60 equivalents of pyrazolamide (green); and (c) 30 equivalents of PABH and 60 equivalents of pyrazolamide (red).
[0021] Figure 14 HRMS analysis of relaxin PEGylated by MCH at its endpoint. The oxime peak overlaps with residual relaxin. The 0.04 min delay of the relaxin peak is due to the influence of the reaction matrix on the chromatographic behavior, rather than late elution impurities.
[0022] Figure 15 Left: Time course of the reaction of relaxin with 20 kDa PEG-OA (1.2 equivalents) in the presence of urea 6M and (a) 30 equivalents of MCH and 30 equivalents of pyrazolamide (red); (b) 30 equivalents of MCH, 30 equivalents of pyrazolamide, and 30 equivalents of NH2OH (blue). Right: Time course of the decomposition of relaxin with PEG-OA (1.2 equivalents) in the presence of urea 6M and 30 equivalents of MCH and 30 equivalents of pyrazolamide (blue); the oxime peak (red) forms during the reaction, indicating the formation of hydroxylamine parallel to the decomposition of PEG-OA.
[0023] Figure 16 Left: Time course of the reaction of relaxin with 20 kDa PEG-OA (1.2 equivalents) in the presence of 30 equivalents of PABH and (a) 60 equivalents of ethylenediamine (gray); (b) 60 equivalents of 3,5-diaminobenzoic acid (green); (c) 60 equivalents of m-phenylenediamine (blue); and 60 equivalents of pyrazolamide (red). Right: Time course of the reaction of relaxin with PEGOA (1.2 equivalents) in the presence of (a) 30 equivalents of PABH and 60 equivalents of 3,5-diaminobenzoic acid (green); and (b) 60 equivalents of PABH and 120 equivalents of NH4Cl (blue).
[0024] Figure 17 Preliminary screening scheme for polyethylene glycol conversion.
[0025] Figure 18 Schemes for the polyethylene glycolation of relaxin and FGF21 in the presence of different amines.
[0026] Figure 19The results of polyethylene glycolation of o-phenylenediamine and m-phenylenediamine, illustrating the curvature of the graph of total equivalent p-amine:PABH ratio versus final FGF21 concentration. Left: o-phenylenediamine. Right: m-phenylenediamine.
[0027] Figure 20 Graph and conversion of total additive equivalents to amine:PABH ratio in polyethylene glycolation using PABH and 3,5-diaminobenzoic acid. Left: FGF21 with 30 kDa PEG-OA. Right: Relaxin with 20 kDa PEG-OA.
[0028] Figure 21 Left: Time progression of the reaction of relaxin with 20 kDa PEG-OA (1.2 equivalents) in the presence of 120 equivalents of salt and 60 equivalents of PABH catalyst, using (a) urea 6M (green); (b) NH4Cl (gray) and (c) (NH4)2SO4.
[0029] Figure 22 Time progression of the reaction of relaxin with 20 kDa PEG-OA (1.2 equivalents) in the absence of additives (blue) and in the presence of (a) 120 equivalents of NH4Cl (red), (b) 60 equivalents of acetylhydrazine (gray), and (c) 60 equivalents of acetylhydrazine and 120 equivalents of NH4Cl (green).
[0030] Figure 23 Left: UV spectra of relaxin before and after the addition of 120 equivalents of NH4Cl (blue and red, respectively). Right: Amino acid sequence of relaxin with aromatic residues highlighted in red.
[0031] Figure 24 Left: IR spectra of relaxin before and after the addition of 120 equivalents of NH4Cl (blue and purple, respectively). Right: IR spectrum inset after the addition of 120 equivalents of NH4Cl, showing a provisional distribution with structural changes.
[0032] Figure 25 Relaxin before and after the addition of 120 equivalents of NH4Cl (red and blue, respectively). 15 N NMRHSQC spectrum.
[0033] Figure 26 Near-UV CD spectra of relaxin before (blue) and after (blue and green, respectively) the addition of 120 equivalents of NH4Cl.
[0034] Figure 27 The structure of potential impurities present in commercial PABH.
[0035] Detailed Explanation Unless otherwise expressly stated elsewhere in this application, the following terms may be used herein and should have the following meanings.
[0036] abbreviation PEG: Polyethylene Glycol PEG-OA: Polyethylene glycol-hydroxyamine mPEG: Methoxy polyethylene glycol MCH: Morpholin-4-formylhydrazine MPCH: 4-Methylpiperazine-1-formylhydrazine pH: Neopentylhydrazine PABH: p-Aminobenzoylhydrazine PMBH: p-Methoxybenzoylhydrazide.
[0037] It must be noted that, unless the context clearly indicates otherwise, the singular forms “a,” “an,” and “the,” as used herein, include plural indicators. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. Unless otherwise stated, all scopes described herein include specific endpoints. The following terms are provided.
[0038] Approximately: The term “approximately” is used in this document to mean approximately, roughly, or around a region. When the term “approximately” is used in conjunction with a numerical range, it modifies the range by expanding the boundaries above and below the listed value. Generally, the term “approximately” is used in this document to modify a value above and below it by a difference of 5% up or down (above or below).
[0039] Additive system: The term "additive system" is used herein to refer to a "catalyst compound" alone or in combination. Examples include p-aminobenzoyl hydrazine alone or in combination with aromatic amines such as 3,5-diaminobenzoic acid, o-phenylenediamine, 1-pyridin-2-yl-ethylamine, 2-(dimethylamino)ethylhydrazine, m-phenylenediamine, and 2-aminomethylpyridine or ammonium salts such as ammonium acetate and ammonium chloride. Preferred catalyst compounds include p-aminobenzoyl hydrazine with 3,5-diaminobenzoic acid, or p-aminobenzoyl hydrazine with ammonium chloride.
[0040] Includes: The term “includes” means “to include”, for example, a composition that “includes” X may consist of only X, or may include other substances, such as X+Y.
[0041] PEG: When used in the context of this disclosure, the term “PEG” refers to polyethylene glycol or a derivative thereof.
[0042] Polyethylene glycolation or PEGylation process: The term “polyethylene glycolation” or “PEGylation process” refers to the process, in the context of this disclosure, of linking a polyethylene glycol (PEG) polymer chain to another molecule containing a protein containing a p-acetylphenylalanine (pAcF) residue, including but not limited to relaxin and FGF21.
[0043] Conjugation: As used herein, the term “conjugation” refers to the conjugation reaction between a protein containing a p-acetylphenylalanine residue and an aminooxy-PEG compound.
[0044] It typically involves the activation of PEG and the direct coupling of the activated PEG-intermediate to the target protein / peptide or linker, which is subsequently activated and coupled to the target protein / peptide (see Abuchowski, A. et al., J. Biol. Chem., 252:3571 (1977) and J. Biol. Chem., 252:3582 (1977), Zalipsky et al., Poly(ethylene glycol) Chemistry: Biotechnical and Biomedical Applications, Chapters 21 and 22, Harris, JM, ed., Plenum Press, NY (1992)). Note that peptides containing PEG molecules are also referred to as conjugated or PEGylated proteins, while proteins lacking conjugated PEG molecules may be referred to as unconjugated or free.
[0045] PEG reagents or polyethylene glycolating agents: reagents that facilitate the polyethylene glycolation reaction.
[0046] It will be understood that any given exemplary implementation may be combined with one or more other exemplary implementations.
[0047] In a first aspect, this disclosure provides an improved additive system for protein polyethylene glycolation reactions, said system comprising p-aminobenzoyl hydrazine alone or in combination with an aromatic amine or an ammonium salt.
[0048] In a first embodiment of the first aspect, the aromatic amine is selected from 3,5-diaminobenzoic acid, o-phenylenediamine, 1-pyridin-2-yl-ethylamine, 2-(dimethylamino)ethylhydrazine, m-phenylenediamine and 2-aminomethylpyridine.
[0049] In a second embodiment of the first aspect, the ammonium salt is selected from ammonium acetate and ammonium chloride.
[0050] In a third embodiment of the first aspect, a preferred system combination comprises p-aminobenzoyl hydrazide with 3,5-diaminobenzoic acid, or p-aminobenzoyl hydrazide with ammonium chloride.
[0051] In a fourth embodiment of the first aspect, the reaction is a conjugation reaction between a protein containing p-acetylphenylalanine residues and an aminooxy-PEG compound.
[0052] In a fifth embodiment of the first aspect, the additive system increases the rate of the conjugation reaction, provides a high yield of the conjugated product, and promotes a reduction in the amount of aminooxy-PEG equivalent required to complete the conjugation reaction.
[0053] In a second aspect, this disclosure provides a method for obtaining polyethylene glycol-modified proteins, the method comprising the steps of: identifying a protein, a PEG reagent, and an additive system; and dissolving the protein, and then mixing the protein with the PEG reagent in the presence of the additive system to obtain polyethylene glycol-modified proteins in high yield.
[0054] In the first embodiment of the second aspect, the protein is relaxin or FGF21 containing pAcF residues.
[0055] In a second embodiment of the second aspect, the dissolved protein solution mixed with the PEG reagent is maintained at a pH of approximately 4.
[0056] In a third embodiment of the second aspect, the reaction mixture is maintained in a temperature range of about 20°C to about 25°C.
[0057] In a fourth embodiment of the second aspect, the additive system comprises p-aminobenzoyl hydrazide alone or a combination thereof with an aromatic amine such as 3,5-diaminobenzoic acid or an ammonium salt such as ammonium acetate or ammonium chloride.
[0058] In the fifth embodiment of the second aspect, the additive combination of high-quality p-aminobenzoyl hydrazine and ammonium chloride is preferably used for the large-scale production of polyethylene glycol-modified proteins.
[0059] In a sixth embodiment of the second aspect, the PEG reagent is selected from PEG-OA and other PEG derivatives having an amino group.
[0060] In a third aspect, this disclosure provides a pharmaceutical composition comprising a polyethylene glycol-modified protein obtained by the method described in the second aspect, and an embodiment thereof for treatment of an individual in need of the protein. Example
[0061] This disclosure will now be described in conjunction with certain embodiments that are not intended to limit its scope. Rather, this disclosure covers all alternatives, modifications, and equivalents that may be included within the scope of the claims. Thus, the following examples, including specific embodiments, will illustrate one practice of this disclosure, and it should be understood that the examples are for the purpose of illustrating certain embodiments and are presented to provide a description of the procedures and concepts that are considered most useful and readily understood.
[0062] The general reaction mechanism between carbonyl and hydroxylamine derivatives is well understood for small molecule reactants (Jencks, WP, Prog. Phys. Org. Chem., 2:63 (1964) and references cited therein). The process is acid-catalyzed and, generally, requires dehydration after a multi-step equilibrium. Although the rate of ketimine formation is slower than that of aldolimine formation due to 1,3-allylic strain, for simple alkoxyamines, the ketone-ketimine equilibrium shifts primarily toward dehydration ( Figure 1 ).
[0063] Example 1 Investigation into the decomposition of polyethylene glycol oxidizing agents as a potential cause of reaction stall One possible cause of PEGylation stall is the decomposition of the PEGylation reagent. Since PEG reagents are not UV-active, different detection methods are needed to monitor their fate during the reaction. Evaporative light scattering (ELS) detection involves passing the HPLC mobile phase through a nebulizer to remove the solvent. Any solid particles that form diffracted light by a laser beam in the detector generate a signal. This method allows the detection of any compound that forms a solid capable of diffracting light. Because PEGylation reagents are high molecular weight solids, they are excellent candidates for HPLC analysis using ELS detection. This is in Figure 2 The difference is quite clear. The UV trace appears green, and the ELS trace appears black. The upper chromatogram (green) is the UV trace at 210 nm, and the black chromatogram is the ELS trace of the same mixture obtained in tandem with the UV detector. Clearly, the black trace at the bottom provides more information, especially for the later-eluted PEG-based compounds.
[0064] The latest elution peak lacks UV activity and is absent at the start of the reaction. This indicates competitive decomposition of the PEGylation reagent. In fact, the compound forms when the PEGylation reagent solution is exposed to air. Figure 3 At a concentration of ≈4 mg / mL, the conversion rate of the 20 kDa PEG-OA reagent is >97%, and it produces non-reactive byproducts in polyethylene glycolation.
[0065] Since this decomposition is a result of the reaction between the PEGylating agent and dissolved gases in the solvent, there should be an inverse correlation between the decomposition rate and concentration. This assumption is consistent with the following observation: 20 kDa PEG-OA samples at more reaction-related concentrations of 30–40 mg / mL are quite stable (<5% decomposition). While this may have some impact on the analytical work of this project to ensure sample stability during analysis, the minimal decomposition under more reaction-related conditions leads to the conclusion that air decomposition of PEG is not a strong cause of the observed reaction stall. The stability of the PEGylating agent in the presence of additives used to accelerate PEGylation was also investigated. These experiments were conducted at the expected reaction concentrations, assuming a target PEG loading of 12 equivalents relative to relaxin. In all cases, the decomposition of the PEGylating agent was minimal.
[0066] Since polyethylene glycolation stall occurs in the presence of a large excess of acetylhydrazine as an accelerating additive, it can be detected via in-situ IR and... 1 ¹H NMR spectroscopy was used to determine the stability of the acetylhydrazine under the reaction conditions. This study shows that acetylhydrazine is stable and indicates that the excess required to promote the reaction is most likely related to the presence of equilibrium and a moderate acceleration relative to the uncatalyzed background process. Figure 4 ).
[0067] Example 2: Study on screening additives using the dipeptide model system (DMS) The initial effort to find additives to accelerate the reaction between the pAcF ketone handle and alkoxyamine in relaxin involved screening commercially available compounds containing an activated X-NH2 moiety that could promote the formation of their corresponding imino derivatives through dehydration. The minimum requirement for selecting these additives was sufficient stability and solubility under the temperature, buffer, and pH conditions used to facilitate the PEGylation of actual proteins in aqueous media. To simplify analytical procedures and facilitate reaction monitoring via HPLC-UV and NMR spectroscopy, dipeptides Ala-pAcF (1) and O-phenylhydroxylamine (2, see [link to relevant documentation]) were selected. Figure 5 The condensation behavior between these components can guide the selection of additives for model conversion. In subsequent steps, additives that improve the model reaction will be tested in the PEGylation of relaxin and FGF21. Figure 5 The model reaction for screening additives is provided. Reaction conditions: 1 (3.6 mmol) and 2 (3.6 mmol), in 1.0 mL acetate buffer (20 mM, pH 4.0), at room temperature (23 °C).
[0068] The reaction rates and conversion percentages of fifty additives were evaluated. Based on the nature of the X substituent on the X-NH2 moiety, the additives were classified into four main categories: aniline, hydrazine, acylhydrazine, and hydrazideformamide. The observed rates were normalized to the rates measured without additives (kJ / kJ). rel =1). Acetylhydrazine (k rel ≈2) is a reference additive for establishing baseline acceptable performance; only by providing k rel Additives with >2 and high conversion rates (>95%) were considered for further application and optimization in the PEGylation of relaxin and FGF21. The results were summarized as follows: Figure 6 The reaction was carried out at room temperature in HPLC vials without stirring to simulate protein PEGylation conditions, and aliquots were periodically ablated using an automated HPLC sampler to avoid further sample manipulation.
[0069] Acylhydrazides (blue) and hydrazideformamide (green) provided the best results. Generally, aniline (red) provided complete dipeptide conversion but did not accelerate the reaction. Furthermore, most anilines promoted high levels of undesirable epimerization. Hydrazine (yellow) formed a large amount of hydrazone under the reaction conditions and was discarded for further investigation. Aromatic acylhydrazides and secondary hydrazideformamides produced up to 5-fold acceleration, as well as high conversion rates, which stalled at approximately 95% dipeptide consumption. In particular, screening led to the discovery of morpholine-4-formylhydrazide (MCH, 4) and p-aminobenzoylhydrazide (PABH, 7) as the best reagents for promoting conversion. Based on their performance, solubility at pH 4, commercial availability, and cost, PABH and MCH were further evaluated in the PEGylation of relaxin and FGF21 (see below).
[0070] With this information, attempts to avoid reaction runaway focused on three areas: (a) adding different amounts of additives, (b) the role of the dissociation agent, and (c) combinations of additives. Initially, studies were conducted using model dipeptides and acetylhydrazine to determine the inherent trends in reactivity. Monitoring the reaction rate at different amounts of acetylhydrazine revealed saturation kinetics in the additives, indicating that the rate increase reached a threshold at high reagent concentrations (Scheme 1).
[0071] Option 1 Keto-ketooxime equilibrium determined by NMR spectroscopy Moreover, consistent with the general mechanism involving the multi-step sequence of reversible imine transfer reactions, increased concentration of acetylhydrazine promoted a higher stall level. In the presence of an accelerator, this mechanism suggests the possibility of achieving better conversion by shifting the apparent equilibrium towards dehydration. Empirical attempts to alter this equilibrium by changing the reaction medium have been unsuccessful. For example, the addition of 6M urea or NH4Cl did not accelerate the reaction or affect the original conversion level. Screening of certain anilines resulted in complete conversion without acceleration, and it is expected that combinations of these anilines with accelerators could help extend substrate conversion. Indeed, the use of a mixture of acetylhydrazine and pyrazolamide 9 resulted in faster reaction characteristics and near-complete conversion. Figure 6 A mixture containing equimolar amounts of dipeptide, pyrazolamide, MCH additive, or a mixture of MCH and pyrazolamide. 1 1H NMR analysis revealed the synergistic growth of imine and hydrazone intermediates in the sample containing the mixture, and indicated that the positive effect of accelerating the combination of additives and aniline was associated with the shift of equilibrium towards the reaction intermediates along the way. Figure 8 ).
[0072] Using PABH, similar additives containing both hydrazide and aniline moieties. 1 1H NMR spectroscopy revealed the widespread formation of a single hydrazone intermediate consistent with DFT calculations. Under neutral conditions, the theoretical B3LYP / 6-31G(d) level, calculated at approximately 3 kcal / mol, favored the formation of a hydrazone between pAcF and PABH, rather than its homoimine (Scheme 2).
[0073] Option 2 The geometry and energy of B3LYP / 6-31G(d) in the hydrazone and imine intermediates that form pAcF under neutral conditions. Protonated amino acid -NH2(pK a ≈9) supports hydrazone formation at ≈9 kcal / mol. Diprotonation (pKa: aniline ≈2.5, hydrazide <2) favors imine formation at ≈1.0 kcal / mol. Although the reaction does not proceed at such low pH values, DFT calculations indicate that dehydration is highly sensitive to pH changes and hydrogen bonding.
[0074] The hydrazone intermediate can be monitored during the polyethylene glycolation of dipeptide 1 and PABH. Figure 9 A control experiment, in the absence of a polyethylene glycol equilibrating agent, equilibrated an overnight mixture of dipeptide 1 and PABH, demonstrating hydrazone formation and its rapid consumption upon addition of 20 kDa PEG-OA to yield the desired product. Amine additives (e.g., pyrazolamide) were also used. Figure 10Further examination of hydrazone formation in the presence of [a specific ingredient] indicated that the extent of hydrazone formation was related to the pyrazolamine:PABH ratio used in the reaction. Interestingly, the extent of hydrazone formation did not correlate with reaction rate or conversion in a simple manner. In the model dipeptide system, a 1:1 pyrazolamine:PABH ratio was optimal for hydrazone formation. However, in terms of reaction rate, the optimal conditions corresponded to an amine:hydrazide ratio of 1:2. Preliminary screening supported the need for a higher amount of hydrazide relative to the amine, where hydrazide was observed to provide a much higher reaction rate than the amine additive. On the other hand, an amine:hydrazide ratio of 3:1 was optimal for dipeptide conversion, consistent with (a) the observation of a significant amount of hydrazone intermediate remaining at the end of the reaction at a low amine:hydrazide ratio, and (b) the detection of reaction reversal after the addition of a "kicker charge" of hydrazide additive. In the experiments presented above, the total equivalent was the sum of PBAH and pyrazolamine. The effect of variations in the total equivalent of additives was addressed by a series of experiments run by varying the amine:hydrazide ratio and the total equivalent of the combined additives. The results are summarized in [the following text is missing from the original extract]. Figure 11 The curvature in the figure indicates that the cooperative effect between the amine and the hydrazide is complex, and that optimizing the reaction conditions may require consideration not only of the total equivalent of the additives but also of the ratio between them.
[0075] Example 3 Protein-relaxin and FGF21 additives accelerate polyethylene glycolation The aim of applying lessons learned from the model system to the PEGylation of relaxin and FGF21 was to reduce the equivalent number of 20 kDa PEG-OA to a maximum of 12 equivalents and shorten the reaction time at room temperature without compromising reaction yield or product quality. To this end, additives identified in the model reaction with relaxin were tested under preliminary reaction conditions developed from a preliminary study. In the presence of 30 equivalents of acetylhydrazine or MCH, the PEGylation of relaxin (21 mg / mL in 20 mMAcONa at pH 40) with 1.5 equivalents of PEG-OA achieved a good conversion (≈90%) after 24 hours at room temperature. In the absence of a catalyst, the reaction under the same conditions resulted in a significantly reduced conversion (≈75%). Consistent with the model system studies, PEGylation was accelerated by the additives, and the reaction with MCH was twice as fast as the reaction with acetylhydrazine. Furthermore, Figure 6The proposed equilibrium is supported by the following observations: (a) the catalytic reaction stalls at a comparable conversion rate; (b) once stalled, adding 30 equivalents of additional additive reduces the conversion level; and (c) once stalled, adding 0.5 equivalents of PEG-OA allows the reaction to achieve a higher conversion rate (≈95%). The trend observed for aniline in the model reaction is similar to the PEGylation of relaxin: adding 30 equivalents of pyrazolamine converts most of the relaxin feedstock without acceleration, and the combination of MCH and pyrazolamine produces 95% conversion in just 8 hours. Efforts to optimize reaction conditions expose complex interactions between variables and encourage the application of DoE studies for deeper insights (Example 4). For example, higher or lower amounts of MCH mixed with 30 equivalents of pyrazolamine do not improve conversion, and using higher temperatures does not promote a faster reaction (…). Figure 12 In the presence of additives MCH, MPCH(5), or PH(6), reducing the PEG-OA charge to 1.2 equivalents under optimized conditions of 15 equivalents resulted in a stall at approximately 85-90% conversion. However, contrary to its negligible effect in the model system, the use of MCH / urea6M improved the reaction completion rate to approximately 95%. Figure 12 ).
[0076] However, in the presence of a PEGylation reagent, the development of PEGylation revealed the formation of impurities with the same retention time as the relaxin raw material but which did not react. HRMS studies showed that the impurities corresponded to oximes at the N-terminal residues of pAcF, and the addition of NH2OH confirmed that the impurities had no effect on PEGylation. Figure 13 Two hypotheses were assumed to explain the source of NH2OH: (a) its presence as an input impurity in the PEGylation reagent, and (b) its formation during the PEGylation reaction. Careful analysis of PEG-OA showed that the NH2OH level in the feedstock was <0.05 ppm, thus proving the first hypothesis false. Consistent with the degradation of the PEGylation reagent during the reaction, monitoring of oxime impurity formation showed a clear increase throughout the PEGylation process. Figure 14 Systematic HRMS studies of additives 4-9 showed that MCH and MPCH promoted the degradation of PEG-OA, while acetylhydrazine, PH, PABH, PMBH, and pyrazolamide did not. Therefore, PABH provides a conversion rate comparable to that of MCH. Figure 6 The cost of PABH is significantly lower than that of 60 U / g, making PABH-mediated polyethylene glycolation optimal. The optimized conditions involved using 30 equivalents of PABH and 60 equivalents of pyrazolamide. These results will subsequently be confirmed by a DoE study.
[0077] Corrections to the effect of aniline on reaction conversion observed during model system screening indicated that, in addition to pyrazolamide, three amines could improve the completion rate. These are m-phenylenediamine, ethylenediamine, and 3,5-diaminobenzoic acid. Using 1.2 equivalents of PEG-OA and 30 equivalents of PABH, the addition of 60 equivalents of amine yielded a conversion of ≈95%. Figure 19 Lower additive stoichiometry leads to lower conversion rates (≈90%) in the short term, but higher conversion rates are gradually achieved over 24 hours.
[0078] Example 4 DoE study to evaluate the interactions between different additive combinations Using the DOE method, the interaction between the amine and hydrazide additives used for the PEGylation of relaxin and FGF21 was further explored, taking into account four variables: (a) the identity of the hydrazide, (b) the identity of the amine, (c) the total equivalent of the additives, and (d) the amine:hydrazide ratio of the additives used. Studies were conducted using relaxin and FGF21 to examine the effects of the amine:hydrazide molar ratio and PEG-OA loading on rate and conversion, and to analyze various amines previously identified in the model system ( Figure 6 The results of these experiments reveal the complex interactions between the amine:hydrazide ratio and indicate that reaction optimization requires careful consideration of the type of amine and the substrate protein.
[0079] In the first round of screening (Table 1), we used combinations of PABH, acetylhydrazine, and neopentanoylhydrazine with pyrazolamide for the polyethylene glycolation of both relaxin and FGF21. Figure 17 ). PEG-OA equivalents and urea concentrations were also considered. Most of the additive systems in this screening exhibited good performance. Compared with previous studies ( Figure 7 and 12 Consistent with this, the 2:1 amine:hydrazide system ranks among the top in promoting high conversion rates. Although neopentanoylhydrazide is an excellent hydrazide additive that can promote high conversion rates and fast reaction rates, new impurities were observed in the reaction mixture, whereas no new impurities were observed in the reaction mixture when using PABH.
[0080] Table 1 Preliminary screening results of relaxin PEGylation Pyrazolamide (equivalent) Acylhydrazine Acylhydrazide (equivalent) Conversion rate (%) 60 Neopentylhydrazine 30 98 60 PABH 30 96 0 Neopentylhydrazine 60 96 30 Acetylhydrazine 10 96
[0081] Repeating the screening with FGF21 yielded similar results (Table 2). PABH proved to be an excellent additive for accelerating the reaction, and as one of the goals of this initiative was to develop a general polyethylene glycolation method applicable to a wide range of protein systems, PABH was selected for further investigation. Further support for the use of PABH as the acylhydrazine component is the fact that it is negative in the AMES test, unlike acetylhydrazine, which is known to be an effective mutagen (Bhide, SV et al., Cancer Lett., 23:235 (1984)).
[0082] Table 2 Preliminary screening results of FGF21 polyethylene glycolation
[0083] After selecting PABH as the acylhydrazide, both relaxin and FGF21 protein were used to screen for combinations of PABH with a wider range of amines (Scheme 3). For these experiments, the following considerations were taken into account: (a) screening for amines previously tested in the model system ( Figure 5 (b) The total additive equivalent (the sum of hydrazides and amines) will be in the range of 20-120, and (c) the reaction time will be limited to 24 hours.
[0084] Option 3 Polyethylene glycolation schemes of relaxin and FGF21 in the presence of different amines Since the first DOE screening was conducted using PABH and pyrazolamide, the primary interest was to determine which amine (or amine class) was most suitable for the PABH-containing additive system. The results of the screening using relaxin and FGF21 are summarized below (Tables 3 and 4, respectively).
[0085] Table 3 Data from the second round of relaxin DoE
[0086] Table 4 Data from FGF21 Round 2
[0087] The PEGylation results of relaxin were consistent across various amines, with generally high conversion rates. On the other hand, for FGF21, 3,5-diaminobenzoic acid appeared to be a good accelerator for PEGylation at amine:PABH ratios of 1.0 and 3.0. Keeping the total equivalents and ratios constant, we can better characterize the effect of amines on conversion. For relaxin, this data is given in Table 5.
[0088] Table 5 Effect of amine selection on the conversion rate of relaxin PEGylation
[0089] For relaxin, the effect of amine additives is evident, but this effect is low given the observed high overall conversion. For FGF21, the effect is more pronounced (Table 6).
[0090] Table 6 Effect of amine selection on the conversion rate of FGF21 polyethylene glycolation
[0091] These data clearly show that the conversion rate is highly dependent on the identity of the amine used in combination with PABH. Achieving these conditions does not necessarily reflect the optimal conditions for the PEGylation reaction; we ranked them by conversion rate to obtain a list of the top five additive combinations for FGF21 (Table 7).
[0092] Table 7 FGF21 is one of the top five additive systems for polyethylene glycolation.
[0093] Ethylenediamine and 3,5-diaminobenzoic acid were the two best performers for the polyethylene glycolation of FGF21 under screening conditions. Because 3,5-diaminobenzoic acid is a relatively inexpensive and readily available crystalline solid, it was considered the preferred additive for the amine:PABH combination. Further support will come from a detailed analysis of the total equivalent amine:PABH ratio. As observed in the model system, the synergistic effect of these two additives is quite complex. In fact, the curvature observed in the model system is more pronounced for the polyethylene glycolation of relaxin and FGF21. Figure 19 The data and trends for FGF21 are shown. Aniline o- and m-phenylenediamines are good additives when used for the PEGylation of FGF21. Interestingly, the plots of the final concentration of the remaining protein against the total equivalent and the amine:PABH ratio provide completely different results. The only structural difference between the two additives is the orientation of the amino groups.
[0094] Since the z-axis represents the final concentration of FGF21 in the reaction mixture, ideal conditions will result in the lowest z-axis value on the graph. For stable processes that allow for smaller variations in reagent loading, a flat graph or one with valleys or depressions is ideal. One additive that meets this requirement is 3,5-diaminobenzoic acid (...). Figure 20 ).
[0095] When used for the polyethylene glycolation of relaxin, 3,5-diaminobenzoic acid also exhibits high conversion rates within a reasonable reaction time. Figure 20 The comparison (left and right) shows that the increased conversion rate is also associated with the protein's identity.
[0096] Example 5 uses simple ammonium salts Given the beneficial effect of amine additives at pH 4, we hypothesized that simple ammonium salts could also improve the PEGylation of relaxin. To this end, a series of experiments were conducted with different amounts of PABH and NH4OAc or NH4Cl, revealing the superiority of the combination of 60 equivalents of PABH and 120 equivalents of NH4Cl to provide the optimal conversion (97%, Table 8) observed at 10 hours. Interestingly, re-examination of the reaction of the model dipeptide in the presence of NH4Cl yielded the same curve as observed without NH4Cl, suggesting that the effect of NH4Cl may be related to the alteration of relaxin structure. Indeed, the addition of known ionizing agents such as urea or (NH4)2SO4 yielded comparable results. Figure 21 The positive effects of NH4Cl appear to be universal, and reappear in the PEGylation of relaxin in the absence of hydrazide additives or in the presence of acetylhydrazide. Figure 22 ).
[0097] Table 8 Used to screen the conversion rates of added dosage and simple ammonium salts. reaction additive Salt Conversion rate (10h) 1 30 equivalent pNHP hydrazide <![CDATA[60 equivalents of NH4OAc]]> 90% 2 30 equivalent pNHP hydrazide <![CDATA[120 equivalents of NH4OAc]]> 94%(x3) 3 60 equivalent pNHP hydrazide <![CDATA[60 equivalents of NH4OAc]]> 95% 4 60 equivalent pNHP hydrazide <![CDATA[120 equivalents of NH4OAc]]> 92% 5 60 equivalent pNHP hydrazide <![CDATA[120 equivalents of NH4Cl]]> 97% 6 30 equivalent pNHP hydrazide <![CDATA[60 equivalents of NH4Cl]]> 95%
[0098] Spectroscopic studies seeking a better understanding of the origin of the NH4Cl effect have shown that salt alters the conformation of relaxin in solution. Although UV spectroscopy could not detect the change in absorbance of aromatic residues (260-290 nm) after the addition of 120 equivalents of NH4Cl... Figure 23 However, infrared spectroscopy indicates the presence of structural modifications to amide II with H bonds. Figure 24 It is speculated that the failure of UV analysis to detect changes in aromatic residues can be traced back to the distal positions of amino acids Tyr (Y), Phe (F), and Trp (W) in relaxin, which largely exposes the residues to the solvent and lacks any important intramolecular interactions.
[0099] Subtle modifications to the structure of relaxin revealed that... 15Further support from NMR HSQC spectroscopy studies is consistent with the following: the protein folds into a higher percentage of random coils after the addition of NH4C1. Figure 25 ), and near-ultraviolet CD studies, which showed that the small differences in the fingerprint region of the relaxin tertiary structure may be due to changes in the dimerization interface ( Figure 26 ).
[0100] Example 6 Typical procedures and results Based on the research reported in this memorandum, it is recommended to use the combination of PABH and NH4Cl on a larger scale. The results for various protein systems are presented in the table below.
[0101] Table 9 1 Conditions: 1.2 equivalents of PEG-OA reagent, 20°C, unless otherwise specified. Conversion was determined by HPLC after a reaction time of 18–24 hours.
[0102] One consideration when using PABH in polyethylene glycolation reactions is the inconsistency in purity of commercially available reagents among suppliers. Large-scale use of 98% PABH results in impurity peaks eluting along with the desired product during chromatography. The separation of these impurities confirms their structures as acylhydrazides and amide impurities present in PABH. Figure 27 ).
[0103] Because of the high stoichiometric amount used in the reaction, even low levels of impurities in the reagent can have an impact. Therefore, it is recommended to pursue the highest available quality of PABH.
[0104] Example 7 The use of additives in typical screening procedures is simple in operation. As a representative example, the polyethylene glycolation of FGF21G1 with 30kDa PEG-OA is given.
[0105] Table 10 Reagents and their concentrations project Dosage (mg) Volume (mL) MW μmol FGF21 solution 20.3 1.0 19585 1.04 PABH 4.7 151.17 31.2 <![CDATA[NH4Cl]]> 6.7 53.49 125 30kDa PEG-OA 39.0 31000 1.26
[0106] program In a clean 1.5 mL vial, add a solution of FGF21 (1.0 mL, 20.3 mg / mL, 1.04 μmol) in 20 mM NaOAc, 6 M urea, pH 4 to solid NH4Cl (6.7 mg, 124.8 μmol). Gently stir the mixture until all solids are dissolved. In a separate vial, combine MPEG 30 kDa (39.0 mg, 1.26 μmol) and PABH (4.7 mg, 31.2 μmol). Transfer the protein solution from the first vial to a second vial containing the polyethylene glycol reagent and PABH, and gently stir the mixture until the solids are dissolved (approximately 20 min). Measure the pH and, if necessary, adjust the mixture to pH 4 using 0.1 M HCl.
[0107] The typical reaction mixture is a homogeneous solution, therefore the reaction solution is maintained at 20–25°C without stirring. Reaction progress is monitored by HPLC using ELS or UV detection at 280 nm. The completion rate of the reaction is assessed by comparing HPLC analysis with an external standard.
[0108] Example 8 Comparison of polyethylene glycolation conditions The ultimate goal of this initiative is to demonstrate the practicality of this new polyethylene glycol (PEG) oxidative process compared to the appropriate procedures at the start of the project and the "state of the art" conditions in the literature. This is primarily to quantify the savings in expensive PEG oxidative reagents achievable by using the recommended combination of additives. Table 11 includes the original conditions for PEG oxidative processes using relaxin and FGF21 G1, as well as PEG oxidative processes mediated by PABH additives.
[0109] Table 11 A comparison of polyethylene glycolation conditions, emphasizing potential cost savings.
[0110] The potential cost reduction for relaxin compounds is purely related to the amount of PEG 20kDa reagent used, as the conversion and yield are comparable for both methods. However, the savings are quite significant for the PEGylation of first-generation FGF21 assets. A combination of more than 50% reduction in PEG loading and a 13% increase in reaction yield results in a 70% reduction in overall production costs. Since the costs of PABH and NH4Cl are very low relative to PEGylation reagents, their use contributes minimally to the overall production cost. In the table below, we compare the PABH conditions with those using acetylhydrazine.
[0111] Table 12 Summary of polyethylene glycolation results for various protein systems and comparison with acetylhydrazine. 1 All reactions were carried out at 20°C without stirring using 1.2 equivalents of polyethylene glycol reagent. 2 The reaction was carried out using 1.5 equivalents of polyethylene glycol reagent.
[0112] The following are some advantages of the additive system in this disclosure: 1) Higher conversion rates are achieved using relatively low amounts of very expensive polyethylene glycol reagents (1.2 equivalents versus 1.5–2.5 equivalents). The table below provides a comparison highlighting the improvements over the older method (standard conditions). The combination of the two additives greatly improved the reaction rate and conversion, and allowed for a significant reduction in PEG loading compared to the original conditions.
[0113] 2) It promotes faster reactions by avoiding the need for high reaction temperatures. Avoiding high temperatures reduces concerns related to protein structure modification and reaction stability.
[0114] 3) Replace acetylhydrazine (Ames positive) with PABH (Ames negative in preliminary studies). Exclude the use of genotoxic substances and related controls in the final product.
[0115] Pharmaceutical Composition The polyethylene glycol-modified proteins prepared according to this disclosure can be further made suitable for injection via mixtures or combinations of other pharmaceutically acceptable carriers or mediators prepared by methods known in the art. Pharmaceutically acceptable carriers used to formulate products of the present invention include saline, human serum albumin, human plasma proteins, etc. The present invention also relates to pharmaceutical compositions comprising the conjugates described above and pharmaceutically acceptable excipients and / or carriers. Such pharmaceutically acceptable carriers can be aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcohol / aqueous solutions, emulsions, or suspensions, including saline and buffer media. Parenteral mediators include sodium chloride solutions, Ringer's dextran, dextran and sodium chloride, lactated Ringer's solution, or non-volatile oils. Intravenous mediators include fluids and nutritional supplements, electrolyte supplements such as those based on Ringer's dextran, etc. Preservatives and other additives, such as antimicrobial agents, antioxidants, chelating agents, inert gases, etc., may also be present. Protein conjugates prepared according to this disclosure can be formulated into pharmaceutical compositions suitable for injection using pharmaceutically acceptable carriers or media, using methods known in the art. See, for example, WO 97 / 09996, WO 97 / 40850, WO 98 / 58660 and WO 99 / 07401 (each of which is hereby incorporated in its entirety by reference).
[0116] It will be apparent to those skilled in the art that this disclosure is not limited to the foregoing disclosure and may be embodied in other specific forms without departing from its essential nature. Therefore, this disclosure is intended to be considered exemplary rather than restrictive in all respects, with reference to the appended claims rather than the foregoing disclosure, and thus all variations falling within the meaning and scope of the equivalents of the claims are intended to be included therein.
Claims
1. An improved additive system for protein PEGylation reactions, the system comprising a combination of p-aminobenzoyl hydrazide and an aromatic amine or ammonium salt; wherein the aromatic amine is 3,5-diaminobenzoic acid; wherein the ammonium salt is selected from the group consisting of ammonium acetate and ammonium chloride; wherein the reaction is a conjugation reaction between a protein containing a p-acetylphenylalanine residue and an aminooxy-PEG compound.
2. The system of claim 1, wherein the additive system increases the rate of the conjugation reaction, provides a high yield of the conjugated product, and promotes a reduction in the amount of aminooxy-PEG equivalent required to complete the conjugation reaction.
3. A method for obtaining polyethylene glycol-modified proteins, the method comprising the following steps: (a) Identification of protein, PEG reagent and additive system; and (b) Dissolve the protein and then mix the protein with a PEG reagent in the presence of an additive system to obtain polyethylene glycol-modified protein in high yield. The additive system comprises p-aminobenzoyl hydrazide alone or a combination of p-aminobenzoyl hydrazide with an aromatic amine or an ammonium salt, wherein the aromatic amine is selected from the group consisting of 3,5-diaminobenzoic acid, o-phenylenediamine, 1-pyridin-2-yl-ethylamine, 2-(dimethylamino)ethylhydrazide, m-phenylenediamine and 2-aminomethylpyridine, and wherein the ammonium salt is selected from the group consisting of ammonium acetate and ammonium chloride; The protein mentioned above is relaxin or FGF21 containing acetylphenylalanine residues; and The PEG reagents mentioned therein are selected from the group consisting of PEG-OA and other PEG derivatives having amino groups.
4. The method of claim 3, wherein the protein-dissolving solution mixed with the PEG reagent is maintained at a pH of about 4.
5. The method of claim 3, wherein the reaction mixture is maintained in a temperature range of 20°C to 25°C.
6. The method of claim 3, wherein the additive system comprises p-aminobenzoyl hydrazide alone or a combination of p-aminobenzoyl hydrazide with 3,5-diaminobenzoic acid or ammonium acetate or ammonium chloride.
7. The method of claim 6, wherein the additive combination of p-aminobenzoyl hydrazine and ammonium chloride is used for large-scale production of polyethylene glycol-modified proteins.
Citation Information
Patent Citations
Pharmaceutical combination preparations containing erythropoietin and iron preparations
WO1997009996A1
Erythropoietin solution preparation
WO1997040850A1
Pharmaceutical combination preparations containing erythropoietin and modified haemoglobins
WO1998058660A1
The use of erythropoietin and iron preparations for producing pharmaceutical combination preparations for treating rheumatic diseases
WO1999007401A2
Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
WO2007056448A2
